Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Use of Statins and Hip Fracture Risk: a Case-Control Study [Užívání statinů a riziko zlomeniny proximálního femuru: případová studie]

A. Del Chiaro, S. Marchetti, PD. Parchi, G. Caprili, E. Ipponi, M. Scaglione

. 2022 ; 89 (2) : 104-107.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22014540

PURPOSE OF THE STUDY To evaluate a possible association between hip fracture and statin use. MATERIAL AND METHODS In this case-control study we compared the use of statins between two groups of 210 patients: the first group (case group) included patients hospitalized for hip fractures while the second group (control group) included patients who did not suffer femur bone injuries. The two groups were matched for age, sex, year of hospitalization and possible confounding factors. Inside the group of cases, we also evaluated the differences in terms of fracture type, presence of previous fragility fracture and mortality between statin users and non-users. RESULTS The use of statins was most common among patients without previous fractures (OR=0.54; 95% CI=0.33-0.89; p=0.0138), especially in older patients (OR=0.40; 95% CI=0.22-0.76). We did not find any significant difference in statin intake between men and women in the control group. In the case group, those who did not use statins were more likely to undergo a medial hip fracture (28.5% vs 16.1%). Patients from case group also presented a greater mortality (27.9% vs 19.35%) and an higher percentage of previous hip fractures (20.11% vs 9.7%). However, they didn't presented a significant higher rate of fragility fractures in other sites. DISCUSSION AND CONCLUSIONS Our study suggests a reduced hip fracture risk, especially in cases aged 80 or more, a different fracture pattern (lower percentage of medial fractures) and a reduced mortality at 9 months in patients treated with HMG-CoA reductase inhibitors, confirming the previous evidences reported in literature. Key words: statin, hip fractures, fracture risk, osteoporosis.

Užívání statinů a riziko zlomeniny proximálního femuru: případová studie

000      
00000naa a2200000 a 4500
001      
bmc22014540
003      
CZ-PrNML
005      
20230224092744.0
007      
ta
008      
220602s2022 xr f 000 0|eng||
009      
AR
024    7_
$2 doi $a 10.55095/achot2022/015
035    __
$a (PubMed)35621399
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Del Chiaro, A. $u Department of Orthopaedics and Trauma Surgery, University of Pisa, Pisa, Italy
245    10
$a Use of Statins and Hip Fracture Risk: a Case-Control Study / $c A. Del Chiaro, S. Marchetti, PD. Parchi, G. Caprili, E. Ipponi, M. Scaglione
246    31
$a Užívání statinů a riziko zlomeniny proximálního femuru: případová studie
520    9_
$a PURPOSE OF THE STUDY To evaluate a possible association between hip fracture and statin use. MATERIAL AND METHODS In this case-control study we compared the use of statins between two groups of 210 patients: the first group (case group) included patients hospitalized for hip fractures while the second group (control group) included patients who did not suffer femur bone injuries. The two groups were matched for age, sex, year of hospitalization and possible confounding factors. Inside the group of cases, we also evaluated the differences in terms of fracture type, presence of previous fragility fracture and mortality between statin users and non-users. RESULTS The use of statins was most common among patients without previous fractures (OR=0.54; 95% CI=0.33-0.89; p=0.0138), especially in older patients (OR=0.40; 95% CI=0.22-0.76). We did not find any significant difference in statin intake between men and women in the control group. In the case group, those who did not use statins were more likely to undergo a medial hip fracture (28.5% vs 16.1%). Patients from case group also presented a greater mortality (27.9% vs 19.35%) and an higher percentage of previous hip fractures (20.11% vs 9.7%). However, they didn't presented a significant higher rate of fragility fractures in other sites. DISCUSSION AND CONCLUSIONS Our study suggests a reduced hip fracture risk, especially in cases aged 80 or more, a different fracture pattern (lower percentage of medial fractures) and a reduced mortality at 9 months in patients treated with HMG-CoA reductase inhibitors, confirming the previous evidences reported in literature. Key words: statin, hip fractures, fracture risk, osteoporosis.
650    _2
$a senioři $7 D000368
650    _2
$a kosti a kostní tkáň $7 D001842
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    12
$a fraktury kyčle $x epidemiologie $x prevence a kontrola $7 D006620
650    _2
$a lidé $7 D006801
650    12
$a statiny $x škodlivé účinky $7 D019161
650    _2
$a mužské pohlaví $7 D008297
650    12
$a osteoporóza $7 D010024
655    _2
$a časopisecké články $7 D016428
700    1_
$a Marchetti, S. $u Department of Orthopaedics and Trauma Surgery, University of Pisa, Pisa, Italy
700    1_
$a Parchi, P. D. $u Department of Orthopaedics and Trauma Surgery, University of Pisa, Pisa, Italy
700    1_
$a Caprili, G. $u Department of Orthopaedics and Trauma Surgery, University of Pisa, Pisa, Italy
700    1_
$a Ipponi, E. $u Department of Orthopaedics and Trauma Surgery, University of Pisa, Pisa, Italy
700    1_
$a Scaglione, M. $u Department of Orthopaedics and Trauma Surgery, University of Pisa, Pisa, Italy
773    0_
$w MED00011021 $t Acta chirurgiae orthopaedicae et traumatologiae Čechoslovaca $x 0001-5415 $g Roč. 89, č. 2 (2022), s. 104-107
856    41
$u https://achot.cz/pdfs/ach/2022/02/03.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 8 $c 507 $y p $z 0
990    __
$a 20220602 $b ABA008
991    __
$a 20230224092736 $b ABA008
999    __
$a ok $b bmc $g 1825234 $s 1165761
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 89 $c 2 $d 104-107 $e $i 0001-5415 $m Acta chirurgiae orthopaedicae et traumatologiae Čechoslovaca $n Acta chir. orthop. traumatol. Čechoslovaca $x MED00011021
LZP    __
$b NLK198 $a Pubmed-20220602

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...